<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20241026001330&amp;utm_medium=rss&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20241026001330&amp;utm_medium=rss&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 26 Oct 2024 04:13:31 +0000</lastbuilddate>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>NAT10 promotes vascular remodelling via mRNA ac4C acetylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study reveals that NAT10 promotes vascular remodelling via mRNA ac4C acetylation, which may be a promising therapeutic target against vascular remodelling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae707. doi: 10.1093/eurheartj/ehae707. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Vascular smooth muscle cell (VSMC) phenotype switching is a pathological hallmark in various cardiovascular diseases. N4-acetylcytidine (ac4C) catalyzed by N-acetyltransferase 10 (NAT10) is well conserved in the enzymatic modification of ribonucleic acid (RNA). NAT10-mediated ac4C acetylation is involved in various physiological and pathological processes, including cardiac remodelling. However, the biological functions and underlying regulatory mechanisms of mRNA ac4C modifications in vascular diseases remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: By combining in-vitro and in-vivo vascular injury models, NAT10 was identified as a crucial protein involved in the promotion of post-injury neointima formation, as well as VSMC phenotype switching. The potential mechanisms of NAT10 in the vascular neointima formation were clarified by RNA sequence (RNA-seq), acetylated mRNA immunoprecipitation sequence (acRIP-seq), and RNA binding protein immunoprecipitation sequence (RIP-seq).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NAT10 and ac4C modifications were upregulated in injured human and rodent arteries. Deletion of NAT10 in VSMCs effectively reduced post-injury neointima formation and VSMC phenotype switching. Further RNA-seq, RIP-seq, and acRIP-seq revealed that NAT10, by its ac4C modification, directly interacts with genes, including integrin-β1 (ITGB1) and collagen type I alpha 2 chain (Col1a2) mRNAs. Taking ITGB1 as one example, it showed that NAT10-mediated ac4C consequently increased ITGB1 mRNA stability and its downstream focal adhesion kinase (FAK) signaling, directly influencing the proliferation of VSMCs and vascular remodelling. The regulation of NAT10 on the VSMC phenotype is of translational significance because the administration of Remodelin, a NAT10 inhibitor, effectively prevents neointima formation by suppressing VSMC proliferation and downregulating ITGB1 expression and deactivating its FAK signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study reveals that NAT10 promotes vascular remodelling via mRNA ac4C acetylation, which may be a promising therapeutic target against vascular remodelling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453784</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae707>10.1093/eurheartj/ehae707</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453784</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Cheng Yu</dc:creator>
<dc:creator>Yue Chen</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Weihong Lin</dc:creator>
<dc:creator>Xin Lin</dc:creator>
<dc:creator>Qiong Jiang</dc:creator>
<dc:creator>Hongjin Liu</dc:creator>
<dc:creator>Wenkun Liu</dc:creator>
<dc:creator>Jing Yang</dc:creator>
<dc:creator>Yu Huang</dc:creator>
<dc:creator>Jun Fang</dc:creator>
<dc:creator>Duofen He</dc:creator>
<dc:creator>Yu Han</dc:creator>
<dc:creator>Shuo Zheng</dc:creator>
<dc:creator>Hongmei Ren</dc:creator>
<dc:creator>Xuewei Xia</dc:creator>
<dc:creator>Junyi Yu</dc:creator>
<dc:creator>Lianglong Chen</dc:creator>
<dc:creator>Chunyu Zeng</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>NAT10 promotes vascular remodelling via mRNA ac4C acetylation</dc:title>
<dc:identifier>pmid:39453784</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae707</dc:identifier>
</item>
<item>
<title>Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Despite an overall good prognosis, low RF-CL patients have reduced risk of myocardial infarction or death when allocated to coronary CTA vs. usual care. Risk is similar in patients with very-low and moderate/high likelihood.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae742. doi: 10.1093/eurheartj/ehae742. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Whether index testing using coronary computed tomography angiography (CTA) improves outcomes in stable chest pain is debated. The risk factor weighted clinical likelihood (RF-CL) model provides likelihood estimation of obstructive coronary artery disease. This study investigated the prognostic effect of coronary CTA vs. usual care by RF-CL estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Large-scale studies randomized patients (N = 13 748) with stable chest pain to coronary CTA as part of the initial work-up in addition to or instead of usual care including functional testing. Patients were stratified according to RF-CL estimates [RF-CL: very-low (≤5%), low (>;5%-15%), and moderate/high (>;15%)]. The primary endpoint was myocardial infarction or death at 3 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The primary endpoint occurred in 313 (2.3%) patients. Event rates were similar in patients allocated to coronary CTA vs. usual care [risk difference (RD) 0.3%, hazard ratio (HR) 0.84 (95% CI 0.67-1.05)]. Overall, 33%, 44%, and 23% patients had very-low, low, and moderate/high RF-CL. Risk was similar in patients with very low and moderate/high RF-CL allocated to coronary CTA vs. usual care [very low: RD 0.3%, HR 1.27 (0.74-2.16); moderate/high: RD 0.5%, HR 0.88 (0.63-1.23)]. Conversely, patients with low RF-CL undergoing coronary CTA had lower event rates [RD 0.7%, HR 0.67 (95% CI 0.47-0.97)]. The number needed to test using coronary CTA to prevent one event within 3 years was 143.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Despite an overall good prognosis, low RF-CL patients have reduced risk of myocardial infarction or death when allocated to coronary CTA vs. usual care. Risk is similar in patients with very-low and moderate/high likelihood.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453783</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae742>10.1093/eurheartj/ehae742</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453783</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Laust Dupont Rasmussen</dc:creator>
<dc:creator>Samuel Emil Schmidt</dc:creator>
<dc:creator>Juhani Knuuti</dc:creator>
<dc:creator>Christiaan Vrints</dc:creator>
<dc:creator>Morten Bøttcher</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Michelle C Williams</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Simon Winther</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials</dc:title>
<dc:identifier>pmid:39453783</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae742</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: the rise and OCEANIC fall of asundexian in atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae728. doi: 10.1093/eurheartj/ehae728. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453777</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae728>10.1093/eurheartj/ehae728</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453777</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: the rise and OCEANIC fall of asundexian in atrial fibrillation</dc:title>
<dc:identifier>pmid:39453777</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae728</dc:identifier>
</item>
<item>
<title>Adults with congenital heart disease: what every cardiologist should know about their care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>As patients with congenital heart disease (CHD) continue to enjoy longer lives, non-congenital cardiologists and other healthcare professionals are increasingly encountering them in their practice and are challenged by their specific needs. Most under- and post-graduate medical training tends to overlook this common pathology, resulting in insufficient awareness of post-repair or post-palliation residual lesions and sequelae from previous interventions. In a strive towards improving the quality...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae716. doi: 10.1093/eurheartj/ehae716. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">As patients with congenital heart disease (CHD) continue to enjoy longer lives, non-congenital cardiologists and other healthcare professionals are increasingly encountering them in their practice and are challenged by their specific needs. Most under- and post-graduate medical training tends to overlook this common pathology, resulting in insufficient awareness of post-repair or post-palliation residual lesions and sequelae from previous interventions. In a strive towards improving the quality of care for this ever-growing cardiovascular patient cohort, it is prudent to outline the areas of concern and specific management needs pertaining to adult patients with CHD and share it with non-CHD professionals. The purpose of this paper is to offer essential guidance to physicians, including cardiologists, when they encounter a patient with CHD in a non-congenital healthcare setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453759</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae716>10.1093/eurheartj/ehae716</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453759</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Werner Budts</dc:creator>
<dc:creator>Katja Prokšelj</dc:creator>
<dc:creator>Daniel Lovrić</dc:creator>
<dc:creator>Polona Kačar</dc:creator>
<dc:creator>Michael A Gatzoulis</dc:creator>
<dc:creator>Margarita Brida</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adults with congenital heart disease: what every cardiologist should know about their care</dc:title>
<dc:identifier>pmid:39453759</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae716</dc:identifier>
</item>
<item>
<title>Gestational diabetes and future cardiovascular diseases: associations by sex-specific genetic data</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrated a suggestive causal relationship between genetic predisposition to gestational diabetes mellitus and the risk of coronary artery disease, which was mainly mediated by Type 2 diabetes and hypertension. These findings highlight targeting modifiable cardiometabolic risk factors may reduce the risk of coronary artery disease in women with a history of gestational diabetes mellitus.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae706. doi: 10.1093/eurheartj/ehae706. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Observational studies have highlighted that gestational diabetes mellitus is associated with a higher risk of cardiovascular diseases, but the causality remains unclear. Herein, the causality between genetic predisposition to gestational diabetes mellitus and the risk of cardiovascular diseases was investigated using sex-specific Mendelian randomization analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Linkage disequilibrium score regression analysis and two-sample Mendelian randomization analysis were applied to infer the genetic correlation and causality, respectively. Mediation analysis was conducted using a two-step Mendelian randomization approach. Sensitivity analyses were performed to differentiate causality from pleiotropy. The genome-wide association study summary statistics for gestational diabetes mellitus were obtained from FinnGen consortium, while for cardiovascular diseases were generated based on individual-level genetic data from the UK Biobank.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Linkage disequilibrium score regression analyses revealed that gestational diabetes mellitus had a significant genetic correlation with coronary artery disease and myocardial infarction after Benjamini-Hochberg correction in ever-pregnant women. In Mendelian randomization analyses, odds ratios (95% confidence interval) for coronary artery disease and myocardial infarction were 1.09 (1.01-1.17) and 1.12 (.96-1.31) per unit increase in the log-odds of genetic predisposition to gestational diabetes mellitus in ever-pregnant women, respectively. Further, Type 2 diabetes and hypertension were identified as mediators for the causality of genetic predisposition to gestational diabetes mellitus on coronary artery disease. In sensitivity analyses, the direction of odds ratio for the association between instrumental variables with gestational diabetes mellitus-predominant effects and the risk of coronary artery disease was consistent with the primary results in ever-pregnant women, although not statistically significant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrated a suggestive causal relationship between genetic predisposition to gestational diabetes mellitus and the risk of coronary artery disease, which was mainly mediated by Type 2 diabetes and hypertension. These findings highlight targeting modifiable cardiometabolic risk factors may reduce the risk of coronary artery disease in women with a history of gestational diabetes mellitus.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453753</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae706>10.1093/eurheartj/ehae706</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453753</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yeshen Zhang</dc:creator>
<dc:creator>Shijie Yu</dc:creator>
<dc:creator>Ziying Chen</dc:creator>
<dc:creator>Haobin Liu</dc:creator>
<dc:creator>Huixian Li</dc:creator>
<dc:creator>Xinyang Long</dc:creator>
<dc:creator>Fei Ye</dc:creator>
<dc:creator>Wenzhi Luo</dc:creator>
<dc:creator>Yining Dai</dc:creator>
<dc:creator>Shan Tu</dc:creator>
<dc:creator>Weikun Chen</dc:creator>
<dc:creator>Siyu Kong</dc:creator>
<dc:creator>Yu He</dc:creator>
<dc:creator>Ling Xue</dc:creator>
<dc:creator>Ning Tan</dc:creator>
<dc:creator>Huiying Liang</dc:creator>
<dc:creator>Zhihui Zhang</dc:creator>
<dc:creator>Pengcheng He</dc:creator>
<dc:creator>Chongyang Duan</dc:creator>
<dc:creator>Yuanhui Liu</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gestational diabetes and future cardiovascular diseases: associations by sex-specific genetic data</dc:title>
<dc:identifier>pmid:39453753</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae706</dc:identifier>
</item>
<item>
<title>Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>There is uncertainty regarding the clinical effects of discontinuation of drugs for heart failure after long-term use. The withdrawal of long-term treatment can follow 1 of 4 distinct patterns: 1) loss of on-treatment effect with no observed changes following discontinuation (eg, prazosin); 2) attenuation or loss of on-treatment effect with rebound clinical worsening following discontinuation (eg, nitroprusside); 3) persistence of deleterious on-treatment effect followed by clinical worsening...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08453-5. doi: 10.1016/j.jacc.2024.09.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is uncertainty regarding the clinical effects of discontinuation of drugs for heart failure after long-term use. The withdrawal of long-term treatment can follow 1 of 4 distinct patterns: 1) loss of on-treatment effect with no observed changes following discontinuation (eg, prazosin); 2) attenuation or loss of on-treatment effect with rebound clinical worsening following discontinuation (eg, nitroprusside); 3) persistence of deleterious on-treatment effect followed by clinical worsening after discontinuation (eg, milrinone and flosequinan); and 4) persistence of favorable on-treatment effect followed by clinical worsening after discontinuation (eg, digoxin and sodium-glucose cotransporter 2 inhibitors). Persuasive evidence for persistence of efficacy has been demonstrated for the use of digoxin, diuretic agents, sodium-glucose cotransporter 2 inhibitors, and (to a limited extent) for angiotensin-converting enzyme inhibitors. Available evidence for worsening of clinical status following the withdrawal of neurohormonal antagonists largely consists of observational studies. However, their findings are difficult to interpret because of considerable confounding related to the fact that drugs were withdrawn for clinical reasons, which represented a more important contributor to the poor outcome of these patients than the withdrawal of an effective drug. Nevertheless, the totality of available evidence points to a meaningful clinical deterioration within a few weeks following the withdrawal for most drugs that have been evaluated for the treatment of heart failure. These findings suggests that that our current emphasis on the implementation of foundational drugs needs to include an equally important emphasis to avoid even short-term gaps in treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453366</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.005>10.1016/j.jacc.2024.09.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453366</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:39453366</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.005</dc:identifier>
</item>
<item>
<title>Genetic Variation and Ablation Outcomes: A Positive Step for Genomic Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 2:S0735-1097(24)08388-8. doi: 10.1016/j.jacc.2024.08.057. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453365</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.057>10.1016/j.jacc.2024.08.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453365</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alan Hanley</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Variation and Ablation Outcomes: A Positive Step for Genomic Medicine</dc:title>
<dc:identifier>pmid:39453365</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.057</dc:identifier>
</item>
<item>
<title>Ambient Temperature and Stroke Risk Among Adults Aged 18-64 Years: A Case-Crossover Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 9:S0735-1097(24)08389-X. doi: 10.1016/j.jacc.2024.08.058. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453364</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.058>10.1016/j.jacc.2024.08.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453364</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Lingzhi Chu</dc:creator>
<dc:creator>Rong Wang</dc:creator>
<dc:creator>Cary P Gross</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Xiaomei Ma</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ambient Temperature and Stroke Risk Among Adults Aged 18-64 Years: A Case-Crossover Study</dc:title>
<dc:identifier>pmid:39453364</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.058</dc:identifier>
</item>
<item>
<title>Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with group 1 PH identifies a subset of patients with worse dynamic PCWP response indicative of subclinical left heart disease, with poorer functional status, quality of life, and survival. Further study in this group 1 PH subgroup is indicated to determine whether PH therapies are effective and safe, and also whether HFpEF-specific therapies can improve functional status and outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08392-X. doi: 10.1016/j.jacc.2024.08.061. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with group 1 pulmonary hypertension (PH) and risk factors for heart failure with preserved ejection fraction (HFpEF) demonstrate worse response to pulmonary vasodilator therapy. The mechanisms and optimal diagnostic approach to identify such patients remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to compare exercise capacity, cardiac function, and hemodynamic responses to provocative maneuvers among patients with group 1 PH based upon pretest probability of HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pretest probability for HFpEF was determined using the validated HFpEF-ABA algorithm based on age, body mass index, and history of atrial fibrillation among group 1 PH patients recruited to the multicenter PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) study. Functional capacity, quality of life, and dynamic pulmonary capillary wedge pressure (PCWP) responses were compared between those with low (&lt;25%), intermediate (25%-74%), and high (≥75%) ABA score-based HFpEF probability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 424 patients with group 1 PH, 54% (n = 228) had intermediate HFpEF probability and 15% (n = 64) had high HFpEF probability. Resting PCWP increased progressively with higher HFpEF probability (P &lt; 0.0001), and patients with group 1 PH and high HFpEF probability had the greatest increases in PCWP with nitric oxide, fluid challenge, and exercise (P &lt; 0.001 for all), changes that were comparable to patients with HFpEF with no pulmonary vascular disease (n = 194), but lower than those with HFpEF and combined precapillary and postcapillary PH. Left ventricular/atrial size, diastolic function, quality of life, 6-minute walk distance, and peak VO<sub>2</sub> were most abnormal in patients with group 1 PH and high HFpEF probability compared with those with low or intermediate HFpEF probability (P &lt; 0.0001 for all). Increasing HFpEF probability in group 1 PH was associated with greater risk of death (HR per decile of HFpEF probability 1.09; 95% CI: 1.05-1.13; P &lt; 0.0001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with group 1 PH identifies a subset of patients with worse dynamic PCWP response indicative of subclinical left heart disease, with poorer functional status, quality of life, and survival. Further study in this group 1 PH subgroup is indicated to determine whether PH therapies are effective and safe, and also whether HFpEF-specific therapies can improve functional status and outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453363</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.061>10.1016/j.jacc.2024.08.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453363</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Robert P Frantz</dc:creator>
<dc:creator>Paul M Hassoun</dc:creator>
<dc:creator>Anna R Hemnes</dc:creator>
<dc:creator>Evelyn Horn</dc:creator>
<dc:creator>Jane A Leopold</dc:creator>
<dc:creator>Franz Rischard</dc:creator>
<dc:creator>Erika B Rosenzweig</dc:creator>
<dc:creator>Nicholas S Hill</dc:creator>
<dc:creator>Serpil C Erzurum</dc:creator>
<dc:creator>Gerald J Beck</dc:creator>
<dc:creator>J Emanuel Finet</dc:creator>
<dc:creator>Christine L Jellis</dc:creator>
<dc:creator>Stephen C Mathai</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:39453363</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.061</dc:identifier>
</item>
<item>
<title>Hemodynamic Insights From Provocative Testing in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 16:S0735-1097(24)09806-1. doi: 10.1016/j.jacc.2024.09.1226. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453362</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1226>10.1016/j.jacc.2024.09.1226</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453362</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Isabela Landsteiner</dc:creator>
<dc:creator>Ashvita Ramesh</dc:creator>
<dc:creator>Bin Q Yang</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hemodynamic Insights From Provocative Testing in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39453362</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1226</dc:identifier>
</item>
<item>
<title>Embryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453361/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SV-derived AF triggers may have hereditary factors with a favorable postablation prognosis, whereas PA-derived triggers are linked to AF persistence and poor ablation response. Variants near PITX2 may play a pivotal role in extra-PV triggers.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 14:S0735-1097(24)08391-8. doi: 10.1016/j.jacc.2024.08.060. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atrial fibrillation (AF) is a prevalent multifactorial arrhythmia associated with specific single-nucleotide polymorphisms (SNPs). Pulmonary vein (PV) isolation is an established treatment for AF; however, recurrence risk remains caused by AF triggers beyond the PVs. Understanding the embryological origins of these triggers could improve treatment outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate the association between embryologically categorized AF triggers, clinical and genetic backgrounds, and postablation prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In cohort 1, comprising 3,067 patients with AF undergoing PV isolation, the clinical characteristics and outcomes were analyzed. Among them, 815 patients underwent genetic analysis using AF-associated SNPs (cohort 2). Patients were delineated based on the developmental origin of the AF triggers: common PV, sinus venosus (SV), and primitive atrium (PA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SV-origin extra-PV AF triggers occurred in 20.3% (n = 622) of patients, whereas PA-origin triggers occurred in 11.9% (n = 365) of patients in cohort 1. Multivariate analysis of cohort 2 revealed that female sex, lower body mass index, absence of hypertension, rs2634073 near PITX2, and rs6584555 in NEURL1 were associated with SV-AF, whereas nonparoxysmal AF and rs2634073 near PITX2 were predictors of PA-AF. The PA group had a significantly higher arrhythmia recurrence rate after repeated procedures than the common PV (HR: 1.75; 95% CI: 1.34-2.29; P &lt; 0.001) and SV-AF (HR: 1.31; 95% CI: 1.19-1.45; P &lt; 0.001) groups with more de novo AF triggers. However, the incidence of adverse events did not differ significantly among the 3 groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SV-derived AF triggers may have hereditary factors with a favorable postablation prognosis, whereas PA-derived triggers are linked to AF persistence and poor ablation response. Variants near PITX2 may play a pivotal role in extra-PV triggers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453361/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453361</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.060>10.1016/j.jacc.2024.08.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453361</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Takashi Ikenouchi</dc:creator>
<dc:creator>Junichi Nitta</dc:creator>
<dc:creator>Osamu Inaba</dc:creator>
<dc:creator>Miho Negishi</dc:creator>
<dc:creator>Miki Amemiya</dc:creator>
<dc:creator>Toshikazu Kono</dc:creator>
<dc:creator>Tasuku Yamamoto</dc:creator>
<dc:creator>Kazuya Murata</dc:creator>
<dc:creator>Iwanari Kawamura</dc:creator>
<dc:creator>Kentaro Goto</dc:creator>
<dc:creator>Takuro Nishimura</dc:creator>
<dc:creator>Tomomasa Takamiya</dc:creator>
<dc:creator>Yukihiro Inamura</dc:creator>
<dc:creator>Kensuke Ihara</dc:creator>
<dc:creator>Susumu Tao</dc:creator>
<dc:creator>Akira Sato</dc:creator>
<dc:creator>Masateru Takigawa</dc:creator>
<dc:creator>Yusuke Ebana</dc:creator>
<dc:creator>Shinsuke Miyazaki</dc:creator>
<dc:creator>Tetsuo Sasano</dc:creator>
<dc:creator>Tetsushi Furukawa</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Embryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39453361</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.060</dc:identifier>
</item>
<item>
<title>Cardiac MRI Predictors of Arrhythmic Sudden Cardiac Events in Patients With Fontan Circulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SCE occurred in 3.5% of the study population, and one-third of patients who experienced SCE died. Mild ventricular dysfunction and dilatation by cardiac magnetic resonance, NYHA functional class, and history of protein-losing enteropathy/plastic bronchitis were associated with SCE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 14:S0735-1097(24)08394-3. doi: 10.1016/j.jacc.2024.08.063. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Among patients with congenital heart disease, those with single ventricles have the highest risk of early mortality. Sudden cardiac death is an important cause of death in this population. Understanding the risk factors for sudden cardiac events (SCE) in Fontan patients could improve prediction and prevention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to determine the prevalence of SCE and risk factors for SCE in the Fontan population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Fontan Outcomes Registry Using CMR Examinations (FORCE) is an international registry collecting clinical and imaging data on Fontan patients. SCE was defined as: 1) cardiac arrest from a shockable rhythm; 2) need for emergent cardioversion/defibrillation; or 3) documented sustained ventricular tachycardia. Univariate and multivariate Cox proportional hazards regression models estimated hazard ratios for predictors of SCE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our sample included 3,132 patients (41% female). The median age at first cardiac magnetic resonance was 14.6 years. SCE was experienced by 3.5% (n = 109) over a median follow-up time of 4.00 years. Of the 109 patients with SCE, 39 (36%) died. On multivariable analysis, NYHA functional class >;II (HR: 4.91; P &lt; 0.0001), history of protein-losing enteropathy/plastic bronchitis (HR: 2.37; P = 0.0082), single-ventricle end-diastolic volume index >;104 mL/m<sup>2</sup> (HR: 3.15; P &lt; 0.0001), and ejection fraction &lt;50% (HR: 1.73; P = 0.0437) were associated with SCE. Kaplan-Meier analysis demonstrated that in patients with none of the above risk factors, the 4-year freedom from SCE was 99.5%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SCE occurred in 3.5% of the study population, and one-third of patients who experienced SCE died. Mild ventricular dysfunction and dilatation by cardiac magnetic resonance, NYHA functional class, and history of protein-losing enteropathy/plastic bronchitis were associated with SCE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453360</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.063>10.1016/j.jacc.2024.08.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453360</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Natasha K Wolfe</dc:creator>
<dc:creator>Mary D Schiff</dc:creator>
<dc:creator>Laura J Olivieri</dc:creator>
<dc:creator>Adam B Christopher</dc:creator>
<dc:creator>Mark Fogel</dc:creator>
<dc:creator>Timothy C Slesnick</dc:creator>
<dc:creator>Rajesh Krishnamurthy</dc:creator>
<dc:creator>Vivek Muthurangu</dc:creator>
<dc:creator>Adam L Dorfman</dc:creator>
<dc:creator>Christopher Z Lam</dc:creator>
<dc:creator>Justin Weigand</dc:creator>
<dc:creator>Joshua D Robinson</dc:creator>
<dc:creator>Rahul H Rathod</dc:creator>
<dc:creator>Tarek Alsaied</dc:creator>
<dc:creator>FORCE Investigators</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac MRI Predictors of Arrhythmic Sudden Cardiac Events in Patients With Fontan Circulation</dc:title>
<dc:identifier>pmid:39453360</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.063</dc:identifier>
</item>
<item>
<title>Assessing Risk of Sudden Death in Patients With Fontan Circulation: Thinking Outside the (Single-Center) Box</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 14:S0735-1097(24)08393-1. doi: 10.1016/j.jacc.2024.08.062. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39453359</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.062>10.1016/j.jacc.2024.08.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453359</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael P DiLorenzo</dc:creator>
<dc:creator>Kanwal M Farooqi</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Assessing Risk of Sudden Death in Patients With Fontan Circulation: Thinking Outside the (Single-Center) Box</dc:title>
<dc:identifier>pmid:39453359</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.062</dc:identifier>
</item>
<item>
<title>Mechanistic study of a low-power bacterial maintenance state using high-throughput electrochemistry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39447571/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>Mechanistic studies of life's lower metabolic limits have been limited due to a paucity of tractable experimental systems. Here, we show that redox-cycling of phenazine-1-carboxamide (PCN) by Pseudomonas aeruginosa supports cellular maintenance in the absence of growth with a low mass-specific metabolic rate of 8.7 × 10^(-4) W (g C)^(-1) at 25°C. Leveraging a high-throughput electrochemical culturing device, we find that non-growing cells cycling PCN tolerate conventional antibiotics but are...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 19:S0092-8674(24)01142-5. doi: 10.1016/j.cell.2024.09.042. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mechanistic studies of life's lower metabolic limits have been limited due to a paucity of tractable experimental systems. Here, we show that redox-cycling of phenazine-1-carboxamide (PCN) by Pseudomonas aeruginosa supports cellular maintenance in the absence of growth with a low mass-specific metabolic rate of 8.7 × 10<sup>-4</sup> W (g C)<sup>-1</sup> at 25°C. Leveraging a high-throughput electrochemical culturing device, we find that non-growing cells cycling PCN tolerate conventional antibiotics but are susceptible to those that target membrane components. Under these conditions, cells conserve energy via a noncanonical, facilitated fermentation that is dependent on acetate kinase and NADH dehydrogenases. Across PCN concentrations that limit cell survival, the cell-specific metabolic rate is constant, indicating the cells are operating near their bioenergetic limit. This quantitative platform opens the door to further mechanistic investigations of maintenance, a physiological state that underpins microbial survival in nature and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39447571/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39447571</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.042>10.1016/j.cell.2024.09.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39447571</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>John A Ciemniecki</dc:creator>
<dc:creator>Chia-Lun Ho</dc:creator>
<dc:creator>Richard D Horak</dc:creator>
<dc:creator>Akihiro Okamoto</dc:creator>
<dc:creator>Dianne K Newman</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanistic study of a low-power bacterial maintenance state using high-throughput electrochemistry</dc:title>
<dc:identifier>pmid:39447571</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.042</dc:identifier>
</item>
<item>
<title>Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39447570/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness costs. We introduce adaptive multi-epitope targeting with enhanced avidity (AMETA), a modular and multivalent nanobody platform that conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold. AMETA can display 20+ nanobodies, enabling...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 21:S0092-8674(24)01143-7. doi: 10.1016/j.cell.2024.09.043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness costs. We introduce adaptive multi-epitope targeting with enhanced avidity (AMETA), a modular and multivalent nanobody platform that conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold. AMETA can display 20+ nanobodies, enabling superior avidity binding to multiple conserved and neutralizing epitopes. By leveraging multi-epitope SARS-CoV-2 nanobodies and structure-guided design, AMETA constructs exponentially enhance antiviral potency, surpassing monomeric nanobodies by over a million-fold. These constructs demonstrate ultrapotent, broad, and durable efficacy against pathogenic sarbecoviruses, including Omicron sublineages, with robust preclinical results. Structural analysis through cryoelectron microscopy and modeling has uncovered multiple antiviral mechanisms within a single construct. At picomolar to nanomolar concentrations, AMETA efficiently induces inter-spike and inter-virus cross-linking, promoting spike post-fusion and striking viral disarmament. AMETA's modularity enables rapid, cost-effective production and adaptation to evolving pathogens.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39447570/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39447570</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.043>10.1016/j.cell.2024.09.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39447570</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yufei Xiang</dc:creator>
<dc:creator>Jialu Xu</dc:creator>
<dc:creator>Briana L McGovern</dc:creator>
<dc:creator>Anna Ranzenigo</dc:creator>
<dc:creator>Wei Huang</dc:creator>
<dc:creator>Zhe Sang</dc:creator>
<dc:creator>Juan Shen</dc:creator>
<dc:creator>Randy Diaz-Tapia</dc:creator>
<dc:creator>Ngoc Dung Pham</dc:creator>
<dc:creator>Abraham J P Teunissen</dc:creator>
<dc:creator>M Luis Rodriguez</dc:creator>
<dc:creator>Jared Benjamin</dc:creator>
<dc:creator>Derek J Taylor</dc:creator>
<dc:creator>Mandy M T van Leent</dc:creator>
<dc:creator>Kris M White</dc:creator>
<dc:creator>Adolfo García-Sastre</dc:creator>
<dc:creator>Peijun Zhang</dc:creator>
<dc:creator>Yi Shi</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy</dc:title>
<dc:identifier>pmid:39447570</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.043</dc:identifier>
</item>
<item>
<title>HFpEF's Fuel Flaw: Impaired Fatty Acid Oxidation Stalls Mitophagy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39446882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 25;135(10):1018-1020. doi: 10.1161/CIRCRESAHA.124.325501. Epub 2024 Oct 24.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39446882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39446882</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11507057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">PMC11507057</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325501>10.1161/CIRCRESAHA.124.325501</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39446882</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Xi Fang</dc:creator>
<dc:creator>Åsa B Gustafsson</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>HFpEF's Fuel Flaw: Impaired Fatty Acid Oxidation Stalls Mitophagy</dc:title>
<dc:identifier>pmid:39446882</dc:identifier>
<dc:identifier>pmc:PMC11507057</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325501</dc:identifier>
</item>
<item>
<title>Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443702/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrosis is one of the main manifestations of atrial cardiomyopathy, an array of electrical, mechanical and structural alterations associated with atrial fibrillation (AF), stroke and heart failure. Atrial fibrosis can be both a cause and a consequence of AF and, once present, it accelerates the progression of AF. The pathophysiological mechanisms leading to atrial fibrosis are diverse and include stretch-induced activation of fibroblasts, systemic inflammatory processes, activation of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 23. doi: 10.1038/s41569-024-01088-w. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrosis is one of the main manifestations of atrial cardiomyopathy, an array of electrical, mechanical and structural alterations associated with atrial fibrillation (AF), stroke and heart failure. Atrial fibrosis can be both a cause and a consequence of AF and, once present, it accelerates the progression of AF. The pathophysiological mechanisms leading to atrial fibrosis are diverse and include stretch-induced activation of fibroblasts, systemic inflammatory processes, activation of coagulation factors and fibrofatty infiltrations. Importantly, atrial fibrosis can occur in different forms, such as reactive and replacement fibrosis. The diversity of atrial fibrosis mechanisms and patterns depends on sex, age and comorbidity profile, hampering the development of therapeutic strategies. In addition, the presence and severity of comorbidities often change over time, potentially causing temporal changes in the mechanisms underlying atrial fibrosis development. This Review summarizes the latest knowledge on the molecular and cellular mechanisms of atrial fibrosis, its association with comorbidities and the sex-related differences. We describe how the various patterns of atrial fibrosis translate into electrophysiological mechanisms that promote AF, and critically appraise the clinical applicability and limitations of diagnostic tools to quantify atrial fibrosis. Finally, we provide an overview of the newest therapeutic interventions under development and discuss relevant knowledge gaps related to the association between clinical manifestations and pathological mechanisms of atrial fibrosis and to the translation of this knowledge to a clinical setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443702/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39443702</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01088-w>10.1038/s41569-024-01088-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443702</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulrich Schotten</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Sander Verheule</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches</dc:title>
<dc:identifier>pmid:39443702</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01088-w</dc:identifier>
</item>
<item>
<title>OpenEP and EP Workbench for electrophysiology data analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443701/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 23. doi: 10.1038/s41569-024-01092-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443701/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39443701</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01092-0>10.1038/s41569-024-01092-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443701</guid>
<pubDate>Thu, 24 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Neil Bodagh</dc:creator>
<dc:creator>Steven E Williams</dc:creator>
<dc:date>2024-10-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>OpenEP and EP Workbench for electrophysiology data analysis</dc:title>
<dc:identifier>pmid:39443701</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01092-0</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1772. doi: 10.1016/j.jacc.2024.09.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39443023</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.026>10.1016/j.jacc.2024.09.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443023</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443023</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.026</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1772. doi: 10.1016/j.jacc.2024.09.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39443022</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.025>10.1016/j.jacc.2024.09.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443022</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443022</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.025</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39443021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241026001330&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 29;84(18):1771. doi: 10.1016/j.jacc.2024.08.055.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39443021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241026001330&v=2.18.0.post9+e462414">39443021</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.055>10.1016/j.jacc.2024.08.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39443021</guid>
<pubDate>Wed, 23 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39443021</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.055</dc:identifier>
</item>





























</channel>
</rss>